Morales Ríos Olga, Jasso Gutiérrez Luis, Talavera Juan O, Téllez-Rojo Martha María, Olivar López Víctor, Garduño Espinosa Juan, Muñoz Hernández Onofre
Int J Clin Pharm. 2016 Feb;38(1):80-7. doi: 10.1007/s11096-015-0209-x.
Physicians identify from 45.7 to 96.2 % of Adverse Drug Reactions (ADRs) in their patients, with under-reporting ranging from 6 to 100 %. In order to improve ADR reporting, several interventions have been evaluated in different studies, but not with regard to ADR identification. In addition, it is not known whether some patient characteristics might influence on ADR identification and reporting by physicians.
(a) To assess the effectiveness of a comprehensive intervention directed to Emergency Department physicians and coordinated by a pharmacist in a tertiary care pediatric hospital on ADR identification and reporting. (b) To assess if some of the children’s characteristics might influence on ADR identification and reporting. Setting The Emergency Department of the Hospital Infantil de México “Federico Gómez”, which is a national pediatric institute of health in México.
A Quasi-experimental, pre-post test trial was designed. During the intervention, the pharmacist gave talks on Pharmacovigilance and on the program for electronic capture of data, took part in patient visits, left reminders, improved accessibility to ADR report format and performed feedback activities. To classify and quantify correctly identified ADRs and ADRs reported to the Institutional Pharmacovigilance Center (IPC), 1136 clinical records were reviewed. The models were adjusted for patient variables.
Total ADRs, ADRs correctly identified by physicians, ADRs reported to the IPC by physicians. Results Before the intervention, 97 % of ADRs were correctly identified and 6.1 % reported by physicians. During the intervention, 99.6 % were correctly identified and 41.2 % were reported, and after the intervention, 99.6 and 41.7 %, respectively. Identification during the intervention showed a sevenfold increase with regard to preintervention and was maintained post-intervention. ADR reporting during the intervention showed a 14-fold increase with regard to pre-intervention and was maintained during post-intervention.
Physicians do identify ADRs, but fail to report them. The intervention increased ADR correct identification and reporting. The effect was maintained after the intervention.
医生能够识别出患者中45.7%至96.2%的药物不良反应(ADR),漏报率在6%至100%之间。为了改善ADR报告情况,不同研究对多种干预措施进行了评估,但未涉及ADR识别方面。此外,尚不清楚某些患者特征是否会影响医生对ADR的识别和报告。
(a)评估在一家三级护理儿科医院,由药剂师协调针对急诊科医生的综合干预措施对ADR识别和报告的有效性。(b)评估儿童的某些特征是否会影响ADR的识别和报告。研究地点为墨西哥“费德里科·戈麦斯”儿童医院急诊科,该医院是墨西哥的一家国立儿科健康机构。
设计了一项准实验性的前后测试试验。在干预期间,药剂师就药物警戒和电子数据采集项目进行讲座,参与患者查房,留下提醒信息,改善获取ADR报告格式的便利性,并开展反馈活动。为了对正确识别的ADR和向机构药物警戒中心(IPC)报告的ADR进行分类和量化,审查了1136份临床记录。对模型进行了患者变量调整。
ADR总数、医生正确识别的ADR、医生向IPC报告的ADR。结果干预前,97%的ADR被正确识别,医生报告率为6.1%。干预期间,99.6%的ADR被正确识别,报告率为41.2%,干预后分别为99.6%和41.7%。干预期间的识别率相较于干预前提高了7倍,并在干预后保持。干预期间的ADR报告率相较于干预前提高了14倍,并在干预后保持。
医生确实能识别ADR,但未能报告。该干预措施提高了ADR的正确识别和报告率。干预后效果得以维持。